BEIJING—Baheal Pharmaceutical Group, a leading healthcare services and distribution company in China, is venturing into a new collaborative endeavor with Fuwai Hospital, Chinese Academy of Medical Sciences (CAMS), to establish a joint research and development center focused on myocardial repair and regeneration drugs. This initiative comes in response to the staggering prevalence of cardiovascular diseases in China, where approximately 330 million people are affected, including 8.9 million heart failure cases, according to the “Report on Cardiovascular Health and Diseases in China 2023.” The report also highlights that cardiovascular diseases account for about 4.3 million deaths annually, with rates escalating due to the aging population.
Previously, Baheal Pharmaceutical Group has demonstrated its commitment to cardiovascular health by incubating Baheal Wisart within the National Center for Cardiovascular Diseases and Fuwai Hospital. This collaboration has successfully harnessed research resources to develop patented technologies based on human primary cardiomyocytes, leading to significant advancements in drug screening, in vitro diagnostic reagents for cardiovascular diseases, and innovative drug development.
Baheal’s innovative spirit is further exemplified by its role in the development of China’s first fully magnetic levitation artificial heart, which possesses complete independent intellectual property rights. This breakthrough technology has been commercialized, providing a lifeline to numerous patients suffering from end-stage heart failure.
The establishment of the joint R&D center with CAMS Fuwai Hospital signifies a significant step forward in the fight against cardiovascular diseases. It underscores Baheal Pharmaceutical Group’s dedication to leveraging scientific research to improve patient outcomes and contribute to the global effort in combating heart-related health issues. – Flcube.com
